Please login to the form below

Not currently logged in
Email:
Password:

J&J to aquire Cougar

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission to purchase all outstanding shares

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission (SEC) to purchase all outstanding shares in Cougar Biotechnology. It reported its intent to acquire the Los Angeles-based biotech company in May this year.

Courgar's board of directors has unanimously approved the merger and, if the deal closes successfully, shareholders will receive $43 per share. The company in-licenses and develops clinical stage oncology drugs and currently has products in trials for prostate cancer, breast cancer, multiple myeloma and solid tumours.

The transaction is expected to close during the third quarter of 2009 and is subject to various conditions.

8th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics